Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1163-1169

  Suzuki, Kazushi ^a   Kokuryo, Toshio ^a   Senga, Takeshi ^a   Yokoyama, Yukihiro ^a   Nagino, Masato ^a   Hamaguchi, Michinari ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ONCOPROTEIN; PROTEIN NEK2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING;

EID: 77953210455     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01504.x     Document Type: Article

References (45)

1. Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 1998, 17:470-81.
2. Uto K, Nakajo N, Sagata N. Two structural variants of Nek2 kinase, termed Nek2A and Nek2B, are differentially expressed in Xenopus tissues and development. Dev Biol 1999, 208:456-64.
3. Fardilha M, WW U, Sa R. Alternatively spliced protein variants as potential therapeutic targets for male infertility and contraception. Ann N Y Acad Sci 2004, 1030:468-78.
4. Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ, Muschel RJ. Inhibition of centrosome separation after DNA damage: a role for Nek2. Radiat Res 2004, 162:128-35.
5. Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene 2002, 21:6184-94.
6. Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res 2007, 67:9637-42.
7. Tsunoda N, Kokuryo T, Oda K. Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci 2009, 100:111-6.
8. Chou T-C, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983, 4:450-4.
9. Shamimi-Noori S, Yeow WS, Ziauddin MF. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 2008, 15:356-70.
10. Grivicich I, Mans DRA, Peters GJ, Schwartsmann G. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res 2001, 34:1087-103.
11. Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-51.
12. Kuebler JP, Wieand HS, O'Connell MJ. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-204.
13. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-310. e1
14. Omura K. Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 2008, 77:13-22.
15. Wong S-F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005, 27:684-94.
16. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006, 13:1845-57.
17. Diaz-Rubio E, Schmoll HJ. The future development of bevacizumab in colorectal cancer. Oncology 2005, 69(Suppl 3):34-45.
18. Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008, 28:742-54.
19. Tol J, Koopman M, Cats A. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-72.
20. Kohne C-H, Lenz H-J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009, 14:478-88.
21. Samantas E, Dervenis C, Rigatos SK. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival. Dig Dis 2007, 25:67-75.
22. Giantonio BJ, Catalano PJ, Meropol NJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-44.
23. Moosmann N, Heinemann V. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008, 8:319-29.
24. O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008, 13:1074-83.
25. Hegde SR, Sun W, Lynch JP. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2008, 2:135-49.
26. Van Cutsem E, Kohne C-H, Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-17.
27. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005, 12:787-95.
28. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Advances in Genetics 2005, 54:117-42.
29. Ameyar-Zazoua M, Guasconi V, Ait-Si-Ali S. siRNA as a route to new cancer therapies. Expert Opin Biol Ther 2005, 5:221-4.
30. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-79.
31. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009, 8:10-6.
32. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007, 334:115-24.
33. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994, 269:787-90.
34. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003, 66:225-37.
35. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-20.
36. Fu G, Ding X, Yuan K. Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis. Cell Res 2007, 17:608-18.
37. Du J, Cai X, Yao J. The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability. Oncogene 2008, 27:4107-14.
38. Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006, 111:974-84.
39. Qiu X-L, Li G, Wu G. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem 2009, 52:1757-67.
40. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005, 41:2449-61.
41. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-400.
42. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004, 116:205-19.
43. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009, 9:501-7.
44. Karasawa H, Miura K, Fujibuchi W. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 2009, 100:903-13.
45. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-{kappa}B p65 subunit. Clin Cancer Res 2004, 10:3333-41.